{"schema_version":"secwatch.filing_event.v1","accession":"0002023658-25-000094","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.847460+00:00","generated_at":"2026-05-17T14:55:59.992757+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bicara Therapeutics Q2 2025: Cash $436.6M, net loss $27.4M; Phase 1/1b data show 54% ORR in HNSCC","bullets":["Cash and equivalents $436.6M as of Jun 30, 2025, expected to fund operations into H1 2029.","Q2 2025 net loss $27.4M vs $17.0M in Q2 2024; R&D expenses $24.8M (up $9M YoY) due to FORTIFI-HN01 trial.","Updated Phase 1/1b data: 54% confirmed ORR, median DOR 21.7 months, median OS 21.3 months in 1L HPV-negative R/M HNSCC.","Additional dose-cohort data (750mg weekly, 2000mg Q2W) expected Q4 2025–Q1 2026; enrollment ongoing in pivotal Phase 2/3.","Pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa + pembrolizumab in 1L R/M HNSCC continues enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0002023658-25-000094","json":"https://secwatch.observer/filing/0002023658-25-000094.json","markdown":"https://secwatch.observer/filing/0002023658-25-000094.md","text":"https://secwatch.observer/filing/0002023658-25-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/0002023658-25-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/bcax-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:55:59.992757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}